Grant Reed
Interventional Cardiology · Cleveland, OHNPI 1922329051
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $175,660 of the $235,061 with a category attached, or 74.7%. Edwards Lifesciences accounts for 60.8% of it on its own, with 12 other manufacturers making up the rest. Among interventional cardiology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $810.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$143K
- Boston Scientific$61K
- Abbott$21K
- Medtronic$10K
- Cardiovascular Systems Inc.$276
- Bayer$137
- plus $153 from 7 others
Across 1 payment — averaging $1715.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
What the payments were for
- Consulting fees$175,66075%
- Speaking & faculty fees$34,76315%
- Travel & lodging$13,9216%
- Food & beverage$10,4354%
- Other$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 80 | $142,816 |
| Boston Scientific | 101 | $61,002 |
| Abbott | 60 | $20,550 |
| Medtronic | 36 | $10,127 |
| Cardiovascular Systems Inc. | 3 | $276 |
| Bayer | 2 | $137 |
| Novartis | 2 | $45 |
| Opsens Inc. | 1 | $25 |
| Pfizer | 1 | $18 |
| BD | 1 | $17 |
| Biotronik Inc. | 1 | $17 |
| Livanova USA, Inc. | 1 | $16 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$122,673
- NAVITOR$17,799
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$16,960
- COREVALVE EVOLUT R$9,343
- CLINICAL TRIAL PRODUCT$5,625
- GENERAL - THERAPIES$5,624
- Vitalyst$5,081
- GENERAL - STRUCTURAL HEART$5,000
- MitraClip$763
- PORTICO$618
- GENERAL VASCULAR ACCESS$551
- SAPIEN 3 Ultra RESILIA$522
- Diamondback Coronary$412
- DRAGONFLY OPSTAR$170
- AVVIGO Guidance System$134
- Interventional Heart Failure Pump$117
- Xience Sierra Coronary Stent System$105
How this compares
$235,061 in reported general payments places this provider in the 95th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $104,368 |
| JardianceEmpagliflozin | 50 | $59,992 |
| Repatha SureclickEvolocumab | 47 | $39,036 |
| EntrestoSacubitril/Valsartan | 25 | $29,104 |
| FarxigaDapagliflozin Propanediol | 15 | $8,476 |
| Ranolazine ErRanolazine | 32 | $3,924 |
| Ezetimibe | 56 | $3,009 |
| Metoprolol Succinate | 115 | $2,492 |
| Atorvastatin Calcium | 146 | $2,118 |
| Rosuvastatin Calcium | 89 | $2,116 |
| ClopidogrelClopidogrel Bisulfate | 105 | $1,106 |
| Losartan Potassium | 67 | $1,057 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 73 | $1,007 |
| Amlodipine Besylate | 110 | $760 |
| Carvedilol | 33 | $407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $104,368100 claims |
| NovartisEntresto | $45 | $29,10425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Cleveland
- Rishi PuriCleveland$185K
- Rayji TsutsuiCleveland$100K
- Paul PoommipanitCleveland$97K
- Jun LiCleveland$85K
- Michael ChenierCleveland$76K
- Khaled ZiadaCleveland$53K
- Laura YoungCleveland$51K
- Bernardo CorteseCleveland$45K
- Jason WenCleveland$37K
- Khanjan ShahCleveland$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.